Weekly Recap: EYLEA, DUPIXENT and LIBTAYO growth and Q3 2026 results

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) heads into its Oct. 30 premarket Q3 2026 report after strong growth driven by EYLEA HD, DUPIXENT and LIBTAYO, highlighting upcoming C5, hem—onc and Factor XI data readouts as it emphasizes science-led strategy and BD; a conference call/webcast follows.P…